Objective: To characterize the posttransplant lymphoproliferative disorders (PTLD) including the Epstein-Barr virus (EBV) status, histological subgroups, site of occurrence and the clinical outcome in the Chinese kidney transplant recipients.
Methods: A retrospective cohort study of 1, 227 adult kidney transplant recipients who were followed up in two transplant centers in Hong Kong over two decades.
Results: 23 (1.9%) patients developed PTLD. Median duration from transplant to PTLD was 104 (5-252) months. Six patients (26.1%) had early PTLD and 17 (73.9%) had late PTLD. Ten (43%) developed PTLD >10 years after transplant. All patients in early PTLD group were EBV-positive. In the late PTLD group, 60% were EBV-negative and 40% EBV-positive. More than 90% of cases were monomorphic PTLD with majority being diffuse large B cell lymphoma. Bone marrow was the most common extranodal site. The overall treatment response rate was 52.2 %. None of the patients developed rejection or relapse after PTLD. At a median follow-up of 9 (1-79) months after PTLD, 18 patients died. Patient survival was 48% at 1 year and 30% at 3 years and death-censored allograft survival was 82% at 1year and 73% at 3 years.
Conclusion: Late PTLD is common. Careful adjustment of immunosuppression, close monitoring of patients, increased awareness and early detection of the disease are essential.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722532 | PMC |
| http://dx.doi.org/10.18632/oncotarget.18890 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Resolution of hypertension after kidney transplantation is associated with improved kidney transplant outcomes: a nationwide cohort study.
J Hypertens
December 2024
Division of Nephrology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine.
Objectives: Patients with advanced chronic kidney disease suffer from hypertension, and kidney transplantation (KT) has potential to induce hypertension resolution. We hypothesized that hypertension resolution after KT is associated with better KT outcomes.
Methods: We identified KT recipients (2006-2015) who had pretransplant hypertension.
Do SGLT2 Inhibitors Protect the Kidneys? An Alternative Explanation.
Endocr Metab Immune Disord Drug Targets
January 2025
Sheba Medical Center, Institute of Endocrinology, Tel-Hashomer, Israel.
SGLT2 inhibitors are a family of drugs that were developed to treat diabetes mellitus. In randomized controlled trials, SGLT2 inhibitors seem to prevent kidney deterioration in patients with nephropathies, both diabetic and non-diabetic. However, in contrast to biochemical/physiological results (proteinuria and serum creatinine levels) that improve in all studies, the clinical results (all-cause mortality, cardiovascular death, need for dialysis, or renal transplant) do not consistently improve.
View Article and Find Full Text PDFLEGMO: Extremity Salvage Using Extracorporeal Membrane Oxygenation.
Ann Thorac Surg Short Rep
March 2023
Department of Vascular Surgery, Saint Luke's Mid America Heart Institute, Kansas City, Missouri.
Mycotic aneurysm management balances the urgency of excising infected vasculature with the need to revascularize in or near an infected field. We present a case of a 47-year-old man with sepsis, a failed kidney transplant, and a ruptured, previously stented right external iliac pseudoaneurysm. After excision of the infected pseudoaneurysm and stents, lower extremity revascularization was delayed through the innovative use of isolated limb perfusion using extracorporeal membrane oxygenation followed by staged extra-anatomic femoral-femoral bypass.
View Article and Find Full Text PDFComplications on the feeding artery after an arterio-venous fistula closure in patients after kidney transplantation - a national cohort study.
Clin Kidney J
January 2025
Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Background: Arteriovenous fistulas (AVFs) in kidney transplant recipients are sometimes closed, either as a policy or due to complications. We collected data on the incidence of complications after AVF closure in a national cohort of transplanted patients.
Methods: Patients who received a kidney transplant between 2000 and 2015 and had a functional AVF that was later ligated or extirpated were included.
Glycogen Storage Disease Type Ia: A Retrospective Claims Analysis of Complications, Resource Utilization, and Cost of Care.
J Health Econ Outcomes Res
January 2025
Ultragenyx Pharmaceutical Inc., Novato, CA, USA.
Glycogen storage disease type Ia (GSDIa) is a rare inherited disorder resulting in potentially life-threatening hypoglycemia, metabolic abnormalities, and complications often requiring hospitalization. This retrospective database analysis assessed the complications, resource utilization, and costs in a large cohort of patients with GSDIa. We conducted a retrospective cohort study of GSDIa patients and matched non-GSDIa comparators utilizing the PharMetrics® Plus database.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!